Medigen Vaccine Biologics Corporation (TPEX:6547)
48.35
-0.95 (-1.93%)
Apr 2, 2025, 1:30 PM CST
Medigen Vaccine Biologics Revenue
In the year 2024, Medigen Vaccine Biologics had annual revenue of 605.64M TWD with 55.44% growth. Medigen Vaccine Biologics had revenue of 128.81M in the quarter ending December 31, 2024, a decrease of -24.82%.
Revenue
605.64M
Revenue Growth
+55.44%
P/S Ratio
26.24
Revenue / Employee
5.88M
Employees
103
Market Cap
15.89B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 605.64M | 216.01M | 55.44% |
Dec 31, 2023 | 389.62M | 24.58M | 6.73% |
Dec 31, 2022 | 365.04M | -2.92B | -88.87% |
Dec 31, 2021 | 3.28B | 3.27B | 28,413.03% |
Dec 31, 2020 | 11.51M | 10.39M | 927.41% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PharmaEssentia | 9.73B |
Caliway Biopharmaceuticals | 44.43M |
Bora Pharmaceuticals Co., LTD. | 19.25B |
Lotus Pharmaceutical | 18.58B |
Oneness Biotech | 117.93M |
Lumosa Therapeutics | 39.15M |
Pegavision | 6.82B |
Polaris Group | 107.00M |